Hi Jeroe,
Just a few snippets that may help.
Not really sure where the trial stands at this point but probably a bit ambitious to expect revenue at this early stage.
Nomura Research Equities: Nov 2011
Action: MSB has been FDA approved to start a Phase III trial for bone-marrow transplantation.
We believe the trial should run for 12 months, with results available 3-6 months after that. These timelines are within our forecasts for timing of potential revenues for MSB.
We continue to forecast first potential sales for MSB from bone-marrow transplant in FY14.
Jefferies Annual Healthcare Conference
New York 2012
Bone Marrow Transplant Cord Blood Product:
Non-core niche market, FDA-cleared Phase 3 program
EU is the major transplant market, plan for early EU regulatory approval by Q1 2013
Mesoblast
Major Accomplishments
Key operational highlights of the 2011 year:
?Commenced our first Phase 3 trial, for bone marrow transplantation
Australian Stock Report: Oct 2011
Bone marrow approval
Mesoblast recently received approval from US authorities to begin an advanced trial of a treatment that could boost the number of bone marrow transplants for patients who cannot find a matched donor.
Following the approval, MSB has commenced the Phase III trial for bone marrow regeneration in patients with blood cancers.
MSB aims to produce a product that can be used in bone marrow transplants where a perfectly matched donor cannot be found.
Bell Potter 2011
MSB has five Phase II trials underway and is initiating a Phase III trial in Bone Marrow Transplant, with a revenue
opportunity matching that of Cochlear. With the FDA requiring only one Phase II and a pivotal trial before approving a successful stem cell therapy, the company has the potential to be yielding commercial revenues by late 2013.
- Forums
- ASX - By Stock
- share price
Hi Jeroe,Just a few snippets that may help. Not really sure...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14500 | $1.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 141676 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14500 | 1.100 |
2 | 93112 | 1.095 |
2 | 37684 | 1.090 |
3 | 40400 | 1.085 |
2 | 61100 | 1.080 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 141676 | 5 |
1.115 | 41050 | 3 |
1.120 | 157964 | 9 |
1.125 | 61233 | 3 |
1.130 | 111595 | 5 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |